The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects.
Macrophage activation plays a key role in liver disease progression. Soluble CD163 (sCD163) is a specific macrophage activation biomarker useful for clinical estimating damage severity and predicting outcome in different liver conditions. sCD163 performance as a non-invasive marker of liver damage w...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0270911&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850023659492605952 |
|---|---|
| author | Victoria Cairoli Elena De Matteo Paola Casciato Beatriz Ameigeiras María Victoria Preciado Pamela Valva |
| author_facet | Victoria Cairoli Elena De Matteo Paola Casciato Beatriz Ameigeiras María Victoria Preciado Pamela Valva |
| author_sort | Victoria Cairoli |
| collection | DOAJ |
| description | Macrophage activation plays a key role in liver disease progression. Soluble CD163 (sCD163) is a specific macrophage activation biomarker useful for clinical estimating damage severity and predicting outcome in different liver conditions. sCD163 performance as a non-invasive marker of liver damage was evaluated in plasma samples at time of biopsy in 120 patients with different hepatic conditions (56 HCV, 20 HCV/HIV, 10 HBV and 34 MAFLD). sCD163 values were compared with those of healthy donors and analyzed related to histological damage. sCD163 together with other clinical parameters were used to create a logistical regression model to predict significant fibrosis. Only patients with viral hepatitis showed higher sCD163 values compared to the control group (HCV p<0.0001; HCV/HIV p<0.0001; HBV p = 0.0003), but no significant differences regarding fibrosis stages were observed. The proposed model predicts fibrosis severity using the logarithm sCD163 concentration, platelet count and age, it demonstrated to be a good marker for the HCV monoinfected group (AUROC 0.834) and an excellent one for the HCV/HIV co-infected group (AUROC 0.997). Moreover, the model displayed a diagnostic performance similar to FIB-4 in HCV cases and FIB-4 and APRI in HCV/HIV coinfected cases, and it even managed to correctly classify some cases that had been misclassified. The proposed model is able to determine, in a non-invasive way, the liver fibrosis stage of HCV and HCV/HIV patients, so after validation, it could be used in a complementary way in the clinical practice whenever APRI and FIB-4 failed to determine damage severity in HCV and HCV/HIV cases. |
| format | Article |
| id | doaj-art-98dfe1108a5e447d99b13748fdc3932e |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-98dfe1108a5e447d99b13748fdc3932e2025-08-20T03:01:19ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01177e027091110.1371/journal.pone.0270911The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects.Victoria CairoliElena De MatteoPaola CasciatoBeatriz AmeigeirasMaría Victoria PreciadoPamela ValvaMacrophage activation plays a key role in liver disease progression. Soluble CD163 (sCD163) is a specific macrophage activation biomarker useful for clinical estimating damage severity and predicting outcome in different liver conditions. sCD163 performance as a non-invasive marker of liver damage was evaluated in plasma samples at time of biopsy in 120 patients with different hepatic conditions (56 HCV, 20 HCV/HIV, 10 HBV and 34 MAFLD). sCD163 values were compared with those of healthy donors and analyzed related to histological damage. sCD163 together with other clinical parameters were used to create a logistical regression model to predict significant fibrosis. Only patients with viral hepatitis showed higher sCD163 values compared to the control group (HCV p<0.0001; HCV/HIV p<0.0001; HBV p = 0.0003), but no significant differences regarding fibrosis stages were observed. The proposed model predicts fibrosis severity using the logarithm sCD163 concentration, platelet count and age, it demonstrated to be a good marker for the HCV monoinfected group (AUROC 0.834) and an excellent one for the HCV/HIV co-infected group (AUROC 0.997). Moreover, the model displayed a diagnostic performance similar to FIB-4 in HCV cases and FIB-4 and APRI in HCV/HIV coinfected cases, and it even managed to correctly classify some cases that had been misclassified. The proposed model is able to determine, in a non-invasive way, the liver fibrosis stage of HCV and HCV/HIV patients, so after validation, it could be used in a complementary way in the clinical practice whenever APRI and FIB-4 failed to determine damage severity in HCV and HCV/HIV cases.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0270911&type=printable |
| spellingShingle | Victoria Cairoli Elena De Matteo Paola Casciato Beatriz Ameigeiras María Victoria Preciado Pamela Valva The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects. PLoS ONE |
| title | The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects. |
| title_full | The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects. |
| title_fullStr | The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects. |
| title_full_unstemmed | The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects. |
| title_short | The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects. |
| title_sort | performance of soluble cd163 as a non invasive biomarker of liver damage in chronically hcv and hcv hiv infected subjects |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0270911&type=printable |
| work_keys_str_mv | AT victoriacairoli theperformanceofsolublecd163asanoninvasivebiomarkerofliverdamageinchronicallyhcvandhcvhivinfectedsubjects AT elenadematteo theperformanceofsolublecd163asanoninvasivebiomarkerofliverdamageinchronicallyhcvandhcvhivinfectedsubjects AT paolacasciato theperformanceofsolublecd163asanoninvasivebiomarkerofliverdamageinchronicallyhcvandhcvhivinfectedsubjects AT beatrizameigeiras theperformanceofsolublecd163asanoninvasivebiomarkerofliverdamageinchronicallyhcvandhcvhivinfectedsubjects AT mariavictoriapreciado theperformanceofsolublecd163asanoninvasivebiomarkerofliverdamageinchronicallyhcvandhcvhivinfectedsubjects AT pamelavalva theperformanceofsolublecd163asanoninvasivebiomarkerofliverdamageinchronicallyhcvandhcvhivinfectedsubjects AT victoriacairoli performanceofsolublecd163asanoninvasivebiomarkerofliverdamageinchronicallyhcvandhcvhivinfectedsubjects AT elenadematteo performanceofsolublecd163asanoninvasivebiomarkerofliverdamageinchronicallyhcvandhcvhivinfectedsubjects AT paolacasciato performanceofsolublecd163asanoninvasivebiomarkerofliverdamageinchronicallyhcvandhcvhivinfectedsubjects AT beatrizameigeiras performanceofsolublecd163asanoninvasivebiomarkerofliverdamageinchronicallyhcvandhcvhivinfectedsubjects AT mariavictoriapreciado performanceofsolublecd163asanoninvasivebiomarkerofliverdamageinchronicallyhcvandhcvhivinfectedsubjects AT pamelavalva performanceofsolublecd163asanoninvasivebiomarkerofliverdamageinchronicallyhcvandhcvhivinfectedsubjects |